Unknown

Dataset Information

0

Recent advances in the understanding and treatment of acute myeloid leukemia.


ABSTRACT: Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.

SUBMITTER: Watts J 

PROVIDER: S-EPMC6081972 | BioStudies | 2018-01-01

SECONDARY ACCESSION(S): NCT02610777

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6749668 | BioStudies
2014-01-01 | S-EPMC4923501 | BioStudies
1000-01-01 | S-EPMC5933364 | BioStudies
2017-01-01 | S-EPMC5526264 | BioStudies
2018-01-01 | S-EPMC5900827 | BioStudies
2020-01-01 | S-EPMC7238648 | BioStudies
2019-01-01 | S-EPMC6591181 | BioStudies
2020-01-01 | S-EPMC7386889 | BioStudies
2015-01-01 | S-EPMC4344862 | BioStudies
2018-01-01 | S-EPMC6246033 | BioStudies